×
About 18,899 results

ALLMedicine™ Non-Hodgkin Lymphoma Center

Research & Reviews  8,759 results

Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis...
https://doi.org/10.1182/bloodadvances.2020003666
Blood Advances; Khurana A, Novo M et. al.

Mar 4th, 2021 - Neurolymphomatosis (NL) is a rare manifestation of lymphoma, with limited evidence for optimal management. The largest patient series, 50 cases of lymphoma and leukemia, was published in 2010 with limited rituximab exposure. This study aims to eva...

American Journal of Hematology: Annual Clinical Updates in Hematologic Malignancies.
https://doi.org/10.1002/ajh.26151
American Journal of Hematology; Susanibar-Adaniya S, Barta SK

Mar 4th, 2021 - Diffuse large B cell lymphoma (DLBCL), the most common type of Non-Hodgkin lymphoma (NHL), comprises a heterogeneous group of diseases with different biology, clinical presentations, and response to treatment. R-CHOP remains the mainstay of therap...

Single nucleotide variants in immune-response genes and the tumor microenvironment comp...
https://doi.org/10.1186/s12885-021-07891-9 10.1002/ajh.25487 10.1182/blood-2007-06-095331 10.1182/blood-2015-11-681460 10.3390/cancers12082120 10.1038/nrc3774 10.18632/oncotarget.8961 10.1002/hon.2106 10.1158/1078-0432.CCR-14-0889 10.1016/j.prp.2018.02.015 10.1097/00130832-200212000-00004 10.1182/blood-2012-04-424630 10.1038/sj.leu.2401664 10.1038/s41375-019-0463-3 10.1016/S1470-2045(05)70434-4 10.1182/blood-2006-11-058040 10.1182/blood-2010-07-295097 10.1080/10428190701615926 10.1093/aje/kwp242 10.3324/haematol.2011.040659 10.1182/blood-2016-01-643569 10.1016/j.omto.2017.12.003 10.1172/JCI59806 10.1111/j.1365-2141.2011.08632.x 10.1158/1055-9965.EPI-10-0389 10.1111/j.1365-2141.2010.08424.x 10.1016/j.leukres.2015.04.005 10.1007/s11033-013-2815-9 10.1038/sj.leu.2401829 10.1111/hel.12119 10.1097/00003246-200301000-00005 10.4049/jimmunol.166.6.3915 10.1111/j.1365-2141.2005.05630.x 10.1016/j.jaci.2012.08.013 10.1093/hmg/8.1.93 10.1097/00007890-199810270-00009 10.1158/0008-5472.CAN-09-3541 10.1016/S0027-5107(01)00217-2 10.1371/journal.pone.0148044 10.1080/2162402X.2017.1356964 10.1371/journal.pone.0034400 10.1182/blood-2013-01-480889 10.1016/j.jaci.2005.12.1346 10.1182/blood-2011-04-346767 10.1371/journal.pone.0225096 10.1007/s00428-020-02750-7 10.1038/nmeth.4346 10.3324/haematol.2015.139493 10.3109/10428199809050913 10.1182/bloodadvances.2016004176 10.1182/blood-2016-06-720490 10.1182/blood-2009-07-235598 10.1038/srep03456 10.1080/2162402X.2015.1030560 10.1073/pnas.0900408106 10.1093/annonc/mdm132 10.5808/GI.2016.14.4.205 10.1016/j.jneuroim.2003.12.001 10.3324/haematol.2009.010264 10.1158/0008-5472.CAN-09-3419 10.1182/blood-2011-12-400580 10.1007/s12308-019-00361-z 10.1016/j.htct.2018.02.004 10.1038/leu.2011.162 10.3324/haematol.2013.095257
BMC Cancer; Assis-Mendonça GR, Fattori A et. al.

Mar 2nd, 2021 - There is evidence to consider that the tumor microenvironment (TME) composition associates with antitumor immune response, and may predict the outcome of various non-Hodgkin lymphoma subtypes. However, in the case of mantle cell lymphoma (MCL), a ...

Aspirin and other nonsteroidal anti-inflammatory drugs, statins, and risk of non-Hodgki...
https://doi.org/10.1002/ijc.33541
International Journal of Cancer; Liebow M, Larson MC et. al.

Mar 1st, 2021 - Non-steroidal anti-inflammatory drugs (NSAIDs) and statin drugs may protect against the development of non-Hodgkin lymphoma (NHL), but data are limited, particularly for NHL subtypes. Further, some in vitro, animal, and epidemiologic data suggest ...

see more →

Guidelines  59 results

Lisocabtagene maraleucel CAR T shows durable response in large B-cell NHL
https://www.healio.com/news/hematology-oncology/20200709/lisocabtagene-maraleucel-car-t-shows-durable-response-in-large-bcell-nhl

Jul 8th, 2020 - In updated results of the pilot study, presented during the ASCO2020 Virtual Scientific Program, researchers showed that lisocabtagene maraleucel induced durable response as a second-line treatment in large B-cell non-Hodgkin lymphoma.

CAR-T continues to show durable responses in indolent non-Hodgkin lymphoma
https://www.healio.com/hematology-oncology/lymphoma/news/online/{b5b2d115-7000-4df9-8743-26711c3bbde1}/car-t-continues-to-show-durable-responses-in-indolent-non-hodgkin-lymphoma

May 30th, 2020 - Axicabtagene ciloleucel induced a 93% response rate among patients with relapsed or refractory indolent non-Hodgkin lymphoma, according to interim results of the phase 2 ZUMA-5 trial presented during the ASCO20 Virtual Scientific Program.

CAR T-Cell Therapy Impresses in Indolent NHL
https://www.medpagetoday.com/meetingcoverage/asco/86783

May 30th, 2020 - Almost 100% of patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) responded to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel, Yescarta), data from an ongoing study showed.

CAR T-Cell Therapy With Axi-Cel Holds Promise in R/R Indolent NHL
https://www.targetedonc.com/view/car-t-cell-therapy-with-axi-cel-holds-promise-in-r-r-indolent-nhl

May 29th, 2020 - Patients with relapsed or refractory indolent non-Hodgkin lymphoma who were treated with the chimeric antigen receptor (CAR) T-cell therapy of axicabtagene ciloleucel (axi-cel; Yescarta) had high rates of complete response (CR) and demonstrated th...

Interim ZUMA-5 Analysis Shows Promise for Axi-Cel in Relapsed/Refractory iNHL
https://www.onclive.com/conference-coverage/asco-2020/interim-analysis-from-phase-ii-zuma5-study-shows-promise-for-axicel-in-rr-inhl

May 29th, 2020 - An interim analysis of the phase II ZUMA-5 study indicated that axicabtagene ciloleucel (axi-cel; Yescarta) demonstrated significant and durable clinical benefit, with high rates of overall response rate (ORR) and complete response (CR) observed, ...

see more →

Drugs  75 results see all →

Clinicaltrials.gov  9,377 results

Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis...
https://doi.org/10.1182/bloodadvances.2020003666
Blood Advances; Khurana A, Novo M et. al.

Mar 4th, 2021 - Neurolymphomatosis (NL) is a rare manifestation of lymphoma, with limited evidence for optimal management. The largest patient series, 50 cases of lymphoma and leukemia, was published in 2010 with limited rituximab exposure. This study aims to eva...

American Journal of Hematology: Annual Clinical Updates in Hematologic Malignancies.
https://doi.org/10.1002/ajh.26151
American Journal of Hematology; Susanibar-Adaniya S, Barta SK

Mar 4th, 2021 - Diffuse large B cell lymphoma (DLBCL), the most common type of Non-Hodgkin lymphoma (NHL), comprises a heterogeneous group of diseases with different biology, clinical presentations, and response to treatment. R-CHOP remains the mainstay of therap...

Single nucleotide variants in immune-response genes and the tumor microenvironment comp...
https://doi.org/10.1186/s12885-021-07891-9 10.1002/ajh.25487 10.1182/blood-2007-06-095331 10.1182/blood-2015-11-681460 10.3390/cancers12082120 10.1038/nrc3774 10.18632/oncotarget.8961 10.1002/hon.2106 10.1158/1078-0432.CCR-14-0889 10.1016/j.prp.2018.02.015 10.1097/00130832-200212000-00004 10.1182/blood-2012-04-424630 10.1038/sj.leu.2401664 10.1038/s41375-019-0463-3 10.1016/S1470-2045(05)70434-4 10.1182/blood-2006-11-058040 10.1182/blood-2010-07-295097 10.1080/10428190701615926 10.1093/aje/kwp242 10.3324/haematol.2011.040659 10.1182/blood-2016-01-643569 10.1016/j.omto.2017.12.003 10.1172/JCI59806 10.1111/j.1365-2141.2011.08632.x 10.1158/1055-9965.EPI-10-0389 10.1111/j.1365-2141.2010.08424.x 10.1016/j.leukres.2015.04.005 10.1007/s11033-013-2815-9 10.1038/sj.leu.2401829 10.1111/hel.12119 10.1097/00003246-200301000-00005 10.4049/jimmunol.166.6.3915 10.1111/j.1365-2141.2005.05630.x 10.1016/j.jaci.2012.08.013 10.1093/hmg/8.1.93 10.1097/00007890-199810270-00009 10.1158/0008-5472.CAN-09-3541 10.1016/S0027-5107(01)00217-2 10.1371/journal.pone.0148044 10.1080/2162402X.2017.1356964 10.1371/journal.pone.0034400 10.1182/blood-2013-01-480889 10.1016/j.jaci.2005.12.1346 10.1182/blood-2011-04-346767 10.1371/journal.pone.0225096 10.1007/s00428-020-02750-7 10.1038/nmeth.4346 10.3324/haematol.2015.139493 10.3109/10428199809050913 10.1182/bloodadvances.2016004176 10.1182/blood-2016-06-720490 10.1182/blood-2009-07-235598 10.1038/srep03456 10.1080/2162402X.2015.1030560 10.1073/pnas.0900408106 10.1093/annonc/mdm132 10.5808/GI.2016.14.4.205 10.1016/j.jneuroim.2003.12.001 10.3324/haematol.2009.010264 10.1158/0008-5472.CAN-09-3419 10.1182/blood-2011-12-400580 10.1007/s12308-019-00361-z 10.1016/j.htct.2018.02.004 10.1038/leu.2011.162 10.3324/haematol.2013.095257
BMC Cancer; Assis-Mendonça GR, Fattori A et. al.

Mar 2nd, 2021 - There is evidence to consider that the tumor microenvironment (TME) composition associates with antitumor immune response, and may predict the outcome of various non-Hodgkin lymphoma subtypes. However, in the case of mantle cell lymphoma (MCL), a ...

Methotrexate - methotrexate tablet-A-S Medication Solutions
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22e10810-16fb-4c84-bccf-972405b77ef8

Mar 2nd, 2021 - Methotrexate tablets is a dihydrofolate reductase inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen (1.1) Treatment of adults w...

see more →

News  627 results

Anti-CD20 Therapy for Lymphoma Tied to Worse COVID-19 Outcomes
https://www.medscape.com/viewarticle/945496

Feb 8th, 2021 - NEW YORK (Reuters Health) - Lymphoma patients treated with B-cell-depleting anti-CD20 monoclonal antibodies, such as rituximab or obinutuzumab, may have worse outcomes from COVID-19 infection, according to a study from France. "More than 20 years ...

Fast Five Quiz: Waldenström Macroglobulinemia Workup
https://reference.medscape.com/viewarticle/944100

Jan 31st, 2021 - Waldenström macroglobulinemia (WM) is an indolent subtype of non-Hodgkin lymphoma (NHL) that affects small lymphocytes. WM is rare, accounting for approximately 2% of hematologic malignancies with 1500 cases diagnosed per year in the United States...

First Data for CAR T-cell Therapy in Follicular Lymphoma: ZUMA-5
https://www.medscape.com/viewarticle/942494

Dec 10th, 2020 - For the first time, a chimeric antigen receptor (CAR) therapy has yielded a high response rate among patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), including patients with follicular lymphoma (FL) and marginal zone lymphom...

Patients With Lung and Blood Cancers Most Vulnerable to COVID-19
https://www.medscape.com/viewarticle/942430

Dec 9th, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Patients with cancer are at significantly increased risk for COVID-19 and worse outcomes, a new review confirms. It also found that patients with ...

CAR T for All R/R DLBCL Patients: The Jury Is Still Out
https://www.medscape.com/viewarticle/939947

Oct 27th, 2020 - Is it time to consider chimeric antigen receptor (CAR) T-cell therapy for all relapsed/refractory diffuse large B-cell lymphoma patients? Maybe not, according to Andrew Zelenetz, MD, PhD. CAR T-cell therapy has demonstrated activity in relapsed/re...

see more →

Patient Education  2 results see all →